Korea Joongang Daily
Korea JoongAng Daily

Biotech and pharmaceutical stocks bullish on U.S. rate cut

Samsung Biologics continued its record-setting streak on Monday to close at 1,087,000 won as other biotech and pharmaceutical shares also soared.

2024-09-23

[EXCLUSIVE] WuXi Biologics CEO dismisses U.S.-China volatility despite decoupling concerns

Wuxi Biologics CEO Chris Chen remains confident in the biopharma industry, even as U.S.-China tensions escalate. He discussed the company's growth challenge, competitive edge and plans for future innovations with the JoongAng Daily.

2024-02-14

As U.S.-China biotech tensions rise, Korea holds its breath

The United States' proposed Biosecure Act has created a volatile market for Chinese firms but has potential benefits for the Korean pharmaceutical industry.

2024-02-14